Leptin reverses nonalcoholic steatohepatitis in patients with severe lipodystrophy

Severe lipodystrophy is characterized by diminished adipose tissue and hypoleptinemia, leading to ectopic triglyceride accumulation. In the liver, this is associated with steatosis, potentially leading to nonalcoholic steatohepatitis (NASH). We investigated the prevalence of NASH and the effect of leptin replacement in these patients. Ten patients with either generalized lipodystrophy (8 patients) or Dunnigan's partial lipodystrophy (2 patients) were included in this analysis. Paired liver biopsy specimens were obtained at baseline and after treatment with recombinant methionyl human leptin (r‐metHuLeptin), mean duration 6.6 months. The extents of portal and parenchymal inflammation, steatosis, ballooning, presence of Mallory bodies, and fibrosis in liver biopsy specimens were scored using a previously validated system developed to assess NASH activity. Histological disease activity was defined as the sum of ballooning, steatosis, and parenchymal inflammation scores. We concurrently tested serum triglycerides and aminotransferases and estimations of liver volume and fat content by magnetic resonance imaging. Eight of 10 patients met histological criteria for NASH at baseline. After treatment with r‐metHuLeptin, repeat histological examinations showed significant improvements in steatosis (P = .006) and ballooning injury (P = .005), with a reduction of mean NASH activity by 60% (P = .002). Fibrosis was unchanged. Significant reductions were seen in mean serum triglycerides (1206→226 mg/dL, P = .002), glucose (220→144 mg/dL, P = .02), insulin (46.4→24.8 μIU/mL, P = .004), ALT (54→24 U/L, P = .02), AST (47→22 U/L, P = .046), liver volume (3209→2391 cm3, P = .007), and liver fat content (31→11%, P = .006). In conclusion, r‐metHuLeptin therapy significantly reduced triglycerides, transaminases, hepatomegaly, and liver fat content. These reductions were associated with significant reductions in steatosis and the hepatocellular ballooning injury seen in NASH. (HEPATOLOGY 2005;41:753–760.)

[1]  M. Jensen,et al.  Leptin, insulin resistance, and liver fibrosis in human nonalcoholic fatty liver disease. , 2004, Journal of hepatology.

[2]  F Fred Poordad,et al.  The role of leptin in NAFLD: contender or pretender? , 2004, Journal of clinical gastroenterology.

[3]  J. Horton,et al.  Molecular mediators of hepatic steatosis and liver injury. , 2004, The Journal of clinical investigation.

[4]  Simeon I. Taylor,et al.  Clinical Course of Genetic Diseases of the Insulin Receptor (Type A and Rabson-Mendenhall Syndromes): A 30-Year Prospective , 2004, Medicine.

[5]  P. Gorden,et al.  Efficacy of recombinant methionyl human leptin therapy for the extreme insulin resistance of the Rabson-Mendenhall syndrome. , 2004, The Journal of clinical endocrinology and metabolism.

[6]  P. Gorden,et al.  Changes in body composition in patients with severe lipodystrophy after leptin replacement therapy. , 2004, Metabolism: clinical and experimental.

[7]  K. Petersen,et al.  Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes. , 2004, The New England journal of medicine.

[8]  L. Orci,et al.  Rapid transformation of white adipocytes into fat-oxidizing machines , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[9]  N. Socci,et al.  Site and mechanism of leptin action in a rodent form of congenital lipodystrophy. , 2004, The Journal of clinical investigation.

[10]  J. Hoofnagle,et al.  A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis , 2004, Hepatology.

[11]  O. Cummings,et al.  Does leptin play a role in the pathogenesis of human nonalcoholic steatohepatitis? , 2003, American Journal of Gastroenterology.

[12]  B. Neuschwander‐Tetri,et al.  Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR‐γ ligand rosiglitazone , 2003, Hepatology.

[13]  M. Reitman,et al.  Liver Peroxisome Proliferator-activated Receptor γ Contributes to Hepatic Steatosis, Triglyceride Clearance, and Regulation of Body Fat Mass* , 2003, Journal of Biological Chemistry.

[14]  L. J. Hardies,et al.  Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes. , 2003, Diabetes.

[15]  D. Mangelsdorf,et al.  PPARα is necessary for the lipopenic action of hyperleptinemia on white adipose and liver tissue , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[16]  I. Leclercq,et al.  Leptin is essential for the hepatic fibrogenic response to chronic liver injury. , 2002, Journal of hepatology.

[17]  K. Petersen,et al.  Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy. , 2002, The Journal of clinical investigation.

[18]  C. Day.  Non-alcoholic steatohepatitis (NASH): where are we now and where are we going? , 2002, Gut.

[19]  Simeon I. Taylor,et al.  Clinical Course of the Syndrome of Autoantibodies to the Insulin Receptor (Type B Insulin Resistance): A 28-Year Perspective , 2002, Medicine.

[20]  M. Reitman,et al.  Leptin-replacement therapy for lipodystrophy. , 2002, The New England journal of medicine.

[21]  Young-Bum Kim,et al.  Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase , 2002, Nature.

[22]  J. Friedman,et al.  Selective deletion of leptin receptor in neurons leads to obesity. , 2001, The Journal of clinical investigation.

[23]  G. Marchesini,et al.  Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. , 2001, Diabetes.

[24]  Y. Takei,et al.  Leptin augments inflammatory and profibrogenic responses in the murine liver induced by hepatotoxic chemicals , 2001, Hepatology.

[25]  S. Caldwell,et al.  A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis , 2001, American Journal of Gastroenterology.

[26]  J. Hoofnagle,et al.  Efficacy and Safety of Troglitazone in the Treatment of Lipodystrophy Syndromes , 2000, Annals of Internal Medicine.

[27]  V. Mootha,et al.  Mechanisms Controlling Mitochondrial Biogenesis and Respiration through the Thermogenic Coactivator PGC-1 , 1999, Cell.

[28]  Z. Younossi,et al.  Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. , 1999, Gastroenterology.

[29]  C. Day,et al.  Non-alcoholic steatohepatitis: another disease of affluence , 1999, The Lancet.

[30]  K. Umesono,et al.  Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. , 1998, The Journal of clinical investigation.

[31]  P. Schmalbrock,et al.  Introduction of fast MR imaging in the assessment of hepatic steatosis. , 1995, Magnetic resonance imaging.

[32]  B. Spiegelman,et al.  Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor , 1994, Cell.

[33]  D. Mitchell,et al.  Fatty liver. Chemical shift phase-difference and suppression magnetic resonance imaging techniques in animals, phantoms, and humans. , 1991, Investigative radiology.

[34]  D. Mitchell,et al.  Fatty Liver: Chemical Shift Phas and Suppression Magnetic Resonance Imaging Techniques in Animals, Phantoms, and Humans , 1991 .

[35]  F. Schaffner,et al.  Fatty liver hepatitis and cirrhosis in obese patients. , 1979, The American journal of medicine.

[36]  S. Sanderson,et al.  The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. , 2005, Journal of hepatology.

[37]  S. Locarnini.  Molecular virology of hepatitis B virus. , 2004, Seminars in liver disease.

[38]  Brian P. Mulhall,et al.  Nonalcoholic steatohepatitis , 2004, Current treatment options in gastroenterology.

[39]  R. Unger,et al.  Lipotoxic diseases. , 2002, Annual review of medicine.

[40]  E. Brunt.  Nonalcoholic Steatohepatitis: Definition and Pathology , 2001, Seminars in liver disease.

[41]  J. Flier,et al.  Characterization of expression of hypothalamic appetite-regulating peptides in obese hyperleptinemic brown adipose tissue-deficient (uncoupling protein-promoter-driven diphtheria toxin A) mice. , 1998, Endocrinology.

[42]  B. Spiegelman,et al.  Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. , 1994, Cell.

[43]  F. Schaffner,et al.  Nonalcoholic fatty liver disease. , 1986, Progress in liver diseases.

[44]  J. Ludwig,et al.  Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. , 1980, Mayo Clinic proceedings.